<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02060188</url>
  </required_header>
  <id_info>
    <org_study_id>CA209-142</org_study_id>
    <secondary_id>2013-003939-30</secondary_id>
    <nct_id>NCT02060188</nct_id>
  </id_info>
  <brief_title>An Investigational Immuno-therapy Study of Nivolumab, and Nivolumab in Combination With Other Anti-cancer Drugs, in Colon Cancer That Has Come Back or Has Spread</brief_title>
  <acronym>CheckMate142</acronym>
  <official_title>A Phase 2 Clinical Trial of Nivolumab, or Nivolumab Combinations in Recurrent and Metastatic Microsatellite High (MSI-H) and Non-MSI-H Colon Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to examine if Nivolumab by itself, or Nivolumab in combination
      with other anti-cancer drugs, will result in meaningful tumor size reduction, in patients
      with colon cancer that has come back or has spread, and who have a specific biomarker in
      their tumors.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Allocation: The Microsatellite Instability High (MSI-High) and C4 and C6 Cohort Parts of the
      trial are Non-randomized, The Non-MSI high Dose Escalation Phase part of the trial contained
      a randomized portion
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">March 7, 2014</start_date>
  <completion_date type="Anticipated">December 31, 2019</completion_date>
  <primary_completion_date type="Anticipated">December 3, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective response rate (ORR) in all MSI-High and non-MSI-High subjects as determined by Investigators</measure>
    <time_frame>The final analysis of the primary endpoint will occur at least 6 months after the last enrolled subject's first dose of study therapy (Approximately up to 34 months)</time_frame>
    <description>(Tumor imaging assessments will occur every 6 weeks from the date of first dose (+/-1 wk) for the first 24 weeks, then every 12 wks (+/- 1 wk) thereafter until disease progression or treatment is discontinued (whichever occurs later)) (Tumor imaging assessments will occur every 6 weeks from the date of first dose (+/-1 wk) for the first 24 weeks, then every 12 wks (+/- 1 wk) thereafter until disease progression or treatment is discontinued (whichever occurs later))</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>ORR in all MSI-H and non-MSI-H subjects based on IRRC determination</measure>
    <time_frame>The final analysis of the secondary endpoint will occur the time of the primary endpoint analysis (Approximately up to 34 months)</time_frame>
    <description>Tumor imaging assessments will occur every 6 weeks from the date of first dose (+/- wk) for the first 24 weeks, then every 12 wks (+/- 1 wk) thereafter until disease progression or treatment is discontinued(whichever occurs later)</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">340</enrollment>
  <condition>Microsatellite Unstable Colorectal Cancer</condition>
  <condition>Microsatellite Stable Colorectal Cancer</condition>
  <condition>Mismatch Repair Proficient Colorectal Cancer</condition>
  <condition>Mismatch Repair Deficient Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>Nivolumab Monotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Nivolumab administered as IV infusion at a dose of 3mg/kg every 2 weeks until disease progression</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Nivolumab (Nivo) + Ipilimumab (Ipi)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Nivo 3mg/Kg IV with Ipi 1 mg/Kg IV every 3 week (wk) for 4 doses followed by Nivo 3mg/Kg IV every 2wk until progression
Dose Escalation Phase: (Complete)
Dose Level (DL) 1: Nivo 0.3mg/Kg with Ipi 1 mg/Kg IV every 3wk for 4 doses followed by Nivo 3mg/Kg IV every 2wk until progression
DL 1: Nivo 1mg/Kg IV with Ipi 1 mg/Kg IV every 3 wk for 4 doses followed by Nivo 3mg/Kg IV every 2wk until progression
DL 2a: Nivo 1mg/Kg IV with Ipi 3 mg/Kg IV every 3wk for 4 doses followed by Nivo 3mg/Kg IV every 2 wk until progression
DL 2b: Nivo 3mg/Kg IV with Ipi 1 mg/Kg IV every 3wk for 4 doses followed by Nivo 3mg/Kg IV every 2 wk until progression</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Nivolumab (Nivo) + Ipilimumab (Ipi) Cohort C3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Nivo IV dosed every 2wk with Ipi IV dosed every 6wk.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Nivolumab (Nivo) + Ipilimumab (Ipi) + Cobimetinib Cohort C4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Nivo IV dosed every 2wk, with Ipi IV dosed every 6wk, combined with Cobimetinib dosed orally once daily 21 days on/7 days off.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Nivolumab (Nivo) + BMS-986016 Cohort C5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Nivo IV dosed every 2wk with BMS-986016 dosed every 2 wk</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Nivolumab (Nivo) + Daratumumab Cohort C6</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Daratumumab IV dosed weekly for week 1-8; then every 2 wks from Week 9-24; then every 4 wks on week 25; with Nivo dosed every 2 wks starting at week 3 and every 4 wks starting at week 25</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ipilimumab</intervention_name>
    <arm_group_label>Nivolumab (Nivo) + Ipilimumab (Ipi)</arm_group_label>
    <arm_group_label>Nivolumab (Nivo) + Ipilimumab (Ipi) Cohort C3</arm_group_label>
    <arm_group_label>Nivolumab (Nivo) + Ipilimumab (Ipi) + Cobimetinib Cohort C4</arm_group_label>
    <other_name>Yervoy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nivolumab</intervention_name>
    <arm_group_label>Nivolumab Monotherapy</arm_group_label>
    <arm_group_label>Nivolumab (Nivo) + Ipilimumab (Ipi)</arm_group_label>
    <arm_group_label>Nivolumab (Nivo) + Ipilimumab (Ipi) Cohort C3</arm_group_label>
    <arm_group_label>Nivolumab (Nivo) + Ipilimumab (Ipi) + Cobimetinib Cohort C4</arm_group_label>
    <arm_group_label>Nivolumab (Nivo) + BMS-986016 Cohort C5</arm_group_label>
    <arm_group_label>Nivolumab (Nivo) + Daratumumab Cohort C6</arm_group_label>
    <other_name>BMS-936558</other_name>
    <other_name>Opdivo</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cobimetinib</intervention_name>
    <arm_group_label>Nivolumab (Nivo) + Ipilimumab (Ipi) + Cobimetinib Cohort C4</arm_group_label>
    <other_name>Cotellic</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Daratumumab</intervention_name>
    <arm_group_label>Nivolumab (Nivo) + Daratumumab Cohort C6</arm_group_label>
    <other_name>Darzalex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>anti-LAG-3 antibody</intervention_name>
    <arm_group_label>Nivolumab (Nivo) + BMS-986016 Cohort C5</arm_group_label>
    <other_name>BMS-986016</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        For more information regarding BMS clinical trial participation, please visit
        www.BMSStudyConnect.com

        Inclusion Criteria:

          -  Men and women â‰¥ 18 years of age

          -  Eastern Cooperative Oncology Group (ECOG) performance status 0 to 1

          -  Histologically confirmed recurrent or metastatic colorectal cancer

          -  Measurable disease by CT or MRI

          -  Testing for MSI Status (by an accredited lab)

               1. Subjects with microsatellite instability high (MSI-H) tumors will enroll in the
                  MSI-H Cohort (mStage and cStage groups), the C3 Cohort, and the C5 Cohort.

               2. Subjects with phenotypes that are non-microsatellite instability high (non-MSI-H)
                  will enroll in the non- MSI-H Safety Cohort and the C6, C4 Cohorts.

          -  Adequate organ function as defined by study-specific laboratory tests

          -  Must use acceptable form of birth control throughout the study. After the final dose
             of study drug, an acceptable form of birth control must be used for 23 weeks for women
             of childbearing potential (WOCBP) and 31 weeks for men who are sexually active with
             WOCBP

          -  Signed informed consent

          -  Willing and able to comply with study procedures

          -  Subjects enrolled into the C3 Cohort must have not had treatment for their metastatic
             disease

        Exclusion Criteria:

          -  Active brain metastases or leptomeningeal metastases are not allowed.

          -  Prior treatment with an anti-Programmed Death Receptor (PD)-1, anti-PD-L1, anti-PD-L2,
             anti-Cytotoxic T-Cell Lymphoma-4 Antigen (CTLA-4) antibody, or any other antibody or
             drug specifically targeting T-cell co-stimulation or immune checkpoint pathways

          -  Prior malignancy active within the previous 3 years except for locally curable cancers

          -  Subjects with active, known or suspected autoimmune disease

          -  Subjects with a condition requiring systemic treatment with either corticosteroids or
             other immunosuppressive medications within 14 days of study drug administration

        Other protocol defined inclusion/exclusion criteria could apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol-Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Banner MD Anderson Cancer Center</name>
      <address>
        <city>Gilbert</city>
        <state>Arizona</state>
        <zip>85234</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>USC Norris Comprehensive Cancer Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pacific Hematology Oncology Associates</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emory University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dana Faber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allina Health System</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55407</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University Office of Research Administration</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novant Health Oncology Specialists</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Providence Cancer Center Oncology and Hematology Care- Eastside</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lehigh Valley Hospital</name>
      <address>
        <city>Allentown</city>
        <state>Pennsylvania</state>
        <zip>18103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Of Pittsburgh Cancer Institute</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University Med Ctr</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232-0021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Md Anderson Can Cnt</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030-4009</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Westmead</city>
        <state>New South Wales</state>
        <zip>2145</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tasman Oncology Research Pty Ltd</name>
      <address>
        <city>Southport</city>
        <state>Queensland</state>
        <zip>4215</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Parkville</city>
        <state>Victoria</state>
        <zip>3050</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Brussels</city>
        <zip>1000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Brussels</city>
        <zip>1090</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 1Z2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 1X5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Paris</city>
        <zip>75012</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Dublin 4</city>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Dublin 9</city>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Galway</city>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Candiolo</city>
        <state>TO</state>
        <zip>10060</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Modena</city>
        <zip>41124</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Padova</city>
        <zip>Padova</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Madrid</city>
        <zip>28009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Madrid</city>
        <zip>28050</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Sevilla</city>
        <zip>41013</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Belgium</country>
    <country>Canada</country>
    <country>France</country>
    <country>Ireland</country>
    <country>Italy</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.fda.gov/MEDWATCH/safety.htm</url>
    <description>FDA Safety Alerts and Recalls</description>
  </link>
  <link>
    <url>http://bms.com/studyconnect/Pages/home.aspx</url>
    <description>BMS Clinical Trial Patient Recruiting</description>
  </link>
  <link>
    <url>http://www.bms.com/clinical_trials/Pages/Investigator_inquiry_form.aspx</url>
    <description>Investigator Inquiry Form</description>
  </link>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 18, 2013</study_first_submitted>
  <study_first_submitted_qc>February 10, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 11, 2014</study_first_posted>
  <last_update_submitted>April 27, 2018</last_update_submitted>
  <last_update_submitted_qc>April 27, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 30, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
    <mesh_term>Colonic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
    <mesh_term>Nivolumab</mesh_term>
    <mesh_term>Daratumumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

